Modality
Multispecific
MOA
CD3xCD20
Target
GPRC5D
Pathway
Neuroinflam
CF
Development Pipeline
Preclinical
~Jul 2017
→ ~Oct 2018
Phase 1
Jan 2019
→ Dec 2028
Phase 1Current
NCT07254838
2,539 pts·CF
2024-11→2028-12·Not yet recruiting
NCT05650552
59 pts·CF
2019-01→2027-07·Not yet recruiting
2,598 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-07-141.3y awayPh2 Data· CF
2028-12-182.7y awayPh2 Data· CF
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1/2
Not yet…
P1/2
Not yet…
Catalysts
Ph2 Data
2027-07-14 · 1.3y away
CF
Ph2 Data
2028-12-18 · 2.7y away
CF
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07254838 | Phase 1/2 | CF | Not yet recr... | 2539 | SeizFreq |
| NCT05650552 | Phase 1/2 | CF | Not yet recr... | 59 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D |